Emergent BioSolutions (EBS) announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000 to the U.S. government. Deliveries are expected to begin this month. This brings the total projected sales for ACAM2000 vaccine and ancillary products to more than $120 million this year from a diverse base of customers. ACAM2000 is licensed for active immunization against smallpox and mpox disease for persons determined to be at high risk for smallpox or mpox infection.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions Advances Pediatric Botulism Antitoxin Study
- Emergent BioSolutions Secures $30M BARDA Contract Extension
- Emergent BioSolutions awarded $30M contract modification for CYFENDUS
- LSBK, EBS, MNSO: Three AI Analyst Stocks With Over 20% Upside
- Emergent BioSolutions’ AIGIV Study: A Potential Game-Changer for Inhalational Anthrax Treatment